The ReproSci project retrospectively analyzed the reproducibility of 1006 claims from 400 papers published between 1959 and 2011 in the field of Drosophila immunity. This project attempts to provide a ...

Overview On January 14, NSFOCUS CERT detected that Microsoft released the January Security Update patch, which fixed 112 security issues involving widely used products such as Windows, Microsoft ...

If you use consumer AI systems, you have likely experienced something like AI "brain fog": You are well into a conversation ...

If the big bottleneck in your Rust development workflow is compile time, there are at least five ways you can fix it.

A large-scale investigation of carnivoran brain diversity, providing a unified description of folding patterns, their relationship to behaviour and ecology, and the foundation for future ...

The world tried to kill Andy off but he had to stay alive to to talk about what happened with databases in 2025.

PythoC lets you use Python as a C code generator, but with more features and flexibility than Cython provides. Here’s a first look at the new C code generator for Python. Python and C share more than ...

A pair of educators at Boylston Elementary School were arrested last week and charged with assaulting multiple children on Nov. 21 at an after-school program, according to a police report. Benjamin ...

Starting today, iPhone users can add their Illinois driver's license or state ID to their Apple Wallet as part of the state's new Mobile ID program. This means residents can now present their ID or ...

LAS VEGAS, Nov. 10, 2025 /PRNewswire/ -- SAFE Structure Designs, a leading Defense Contractor of ergonomic safety-first support equipment, announced today that it has been awarded multiple consecutive ...

A new state report has cited a Stillwater-area substance abuse treatment program for more than 100 breaches of state law or rules, confirming what whistleblowers long suspected. Last summer, several ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...